Current state of immunotherapy for glioblastoma

By M. Lim, Yuanxuan Xia, C. Bettegowda, Michael Weller. Nature Reviews Clinical Oncology, 2018

1,159 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells (2020, background): “However, although they show some clinical efficacy in a subset of BrM patients (Hendriks et al., 2019; Long et al., 2018; Tawbi et al., 2018), ICB has only resulted in responses in isolated cases of primary gliomas to date (Lim et al., 2018; Schalper et al., 2019).”
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma (2020, background): “Accumulating evidence suggests that immune cells are able to enter, proliferate, and function in the central nervous system(CNS), and residentmacrophagescanexpressmajor histocompatibility complex II antigens andT-cell costimulatory cytokines on activation.(5) These data and results from murineglioma”
mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, methodology): “Glioblastoma: mRNA vaccination has been considered a promising strategy to treat glioblastoma.(368) DC-based mRNA vaccines were generated by using mRNA copies of glioblastoma in patients and prolonged progression-free survival 2.”